The Cooper Companies, Inc. (NASDAQ:COO) Receives $117.00 Average PT from Analysts

Shares of The Cooper Companies, Inc. (NASDAQ:COO) have been assigned an average rating of “Moderate Buy” from the twelve analysts that are presently covering the stock, MarketBeat.com reports. Three research analysts have rated the stock with a hold recommendation and nine have given a buy recommendation to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $117.00.

A number of analysts have recently commented on COO shares. Piper Sandler upped their target price on Cooper Companies from $115.00 to $120.00 and gave the stock an “overweight” rating in a research note on Thursday, August 29th. Stifel Nicolaus restated a “buy” rating and issued a $115.00 price objective (up previously from $110.00) on shares of Cooper Companies in a research report on Thursday, August 29th. StockNews.com lowered shares of Cooper Companies from a “buy” rating to a “hold” rating in a report on Wednesday, December 11th. Needham & Company LLC reiterated a “hold” rating on shares of Cooper Companies in a research note on Friday, December 6th. Finally, Morgan Stanley dropped their price target on shares of Cooper Companies from $104.00 to $102.00 and set an “equal weight” rating on the stock in a research report on Friday, December 6th.

Cooper Companies Stock Down 0.5 %

NASDAQ:COO opened at $91.93 on Friday. The company has a current ratio of 1.91, a quick ratio of 1.12 and a debt-to-equity ratio of 0.32. Cooper Companies has a twelve month low of $84.76 and a twelve month high of $112.38. The company has a market cap of $18.35 billion, a PE ratio of 47.14, a P/E/G ratio of 2.52 and a beta of 0.97. The company’s 50 day moving average is $102.46 and its two-hundred day moving average is $98.90.

Cooper Companies (NASDAQ:COO) last issued its quarterly earnings results on Thursday, December 5th. The medical device company reported $1.04 EPS for the quarter, topping analysts’ consensus estimates of $1.00 by $0.04. The company had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1.03 billion. Cooper Companies had a return on equity of 9.38% and a net margin of 10.07%. The firm’s revenue was up 9.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.87 EPS. Analysts anticipate that Cooper Companies will post 3.98 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in COO. LRI Investments LLC raised its stake in Cooper Companies by 4.5% during the 2nd quarter. LRI Investments LLC now owns 2,595 shares of the medical device company’s stock worth $227,000 after acquiring an additional 112 shares in the last quarter. Mitchell & Pahl Private Wealth LLC increased its position in shares of Cooper Companies by 1.5% during the third quarter. Mitchell & Pahl Private Wealth LLC now owns 7,986 shares of the medical device company’s stock worth $881,000 after purchasing an additional 117 shares in the last quarter. Commonwealth Equity Services LLC lifted its holdings in shares of Cooper Companies by 0.8% in the 2nd quarter. Commonwealth Equity Services LLC now owns 15,600 shares of the medical device company’s stock valued at $1,362,000 after purchasing an additional 118 shares during the last quarter. Bleakley Financial Group LLC boosted its position in shares of Cooper Companies by 2.1% in the 3rd quarter. Bleakley Financial Group LLC now owns 5,767 shares of the medical device company’s stock valued at $636,000 after purchasing an additional 119 shares during the period. Finally, First Horizon Advisors Inc. grew its stake in Cooper Companies by 4.8% during the 2nd quarter. First Horizon Advisors Inc. now owns 2,709 shares of the medical device company’s stock worth $236,000 after buying an additional 125 shares during the last quarter. Hedge funds and other institutional investors own 24.39% of the company’s stock.

Cooper Companies Company Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.